Nothing Special   »   [go: up one dir, main page]

FR22C1029I1 - NEW POLYMERIC HGH PRODRUGS - Google Patents

NEW POLYMERIC HGH PRODRUGS

Info

Publication number
FR22C1029I1
FR22C1029I1 FR22C1029C FR22C1029C FR22C1029I1 FR 22C1029 I1 FR22C1029 I1 FR 22C1029I1 FR 22C1029 C FR22C1029 C FR 22C1029C FR 22C1029 C FR22C1029 C FR 22C1029C FR 22C1029 I1 FR22C1029 I1 FR 22C1029I1
Authority
FR
France
Prior art keywords
new polymeric
polymeric hgh
prodrugs
hgh prodrugs
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1029C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma Endocrinology Division AS
Original Assignee
Ascendis Pharma Endocrinology Division AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1029(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Endocrinology Division AS filed Critical Ascendis Pharma Endocrinology Division AS
Publication of FR22C1029I1 publication Critical patent/FR22C1029I1/en
Application granted granted Critical
Publication of FR22C1029I2 publication Critical patent/FR22C1029I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Forests & Forestry (AREA)
  • Ecology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR22C1029C 2014-11-18 2022-06-10 NEW POLYMERIC HGH PRODRUGS Active FR22C1029I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs
EP15797642.4A EP3237014B1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (2)

Publication Number Publication Date
FR22C1029I1 true FR22C1029I1 (en) 2022-09-09
FR22C1029I2 FR22C1029I2 (en) 2023-04-14

Family

ID=51951624

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1029C Active FR22C1029I2 (en) 2014-11-18 2022-06-10 NEW POLYMERIC HGH PRODRUGS

Country Status (26)

Country Link
US (2) US10799563B2 (en)
EP (3) EP3653227B9 (en)
JP (5) JP6783782B2 (en)
KR (2) KR20230152187A (en)
AU (3) AU2015348633C1 (en)
BR (1) BR112017009798A8 (en)
CA (1) CA2968282A1 (en)
CY (2) CY1123963T1 (en)
DK (2) DK3653227T5 (en)
ES (2) ES2947818T3 (en)
FI (2) FI3237014T3 (en)
FR (1) FR22C1029I2 (en)
HR (1) HRP20210400T4 (en)
HU (2) HUE053855T2 (en)
IL (2) IL307773A (en)
LT (2) LT3653227T (en)
MX (2) MX2017006113A (en)
NL (1) NL301172I2 (en)
NO (1) NO2022014I1 (en)
PL (1) PL3653227T6 (en)
PT (1) PT3653227T (en)
RS (1) RS61734B2 (en)
RU (1) RU2718664C2 (en)
SG (2) SG11201703870UA (en)
SI (1) SI3653227T1 (en)
WO (1) WO2016079114A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
EP3988083A1 (en) * 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
NZ751746A (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
KR20200139730A (en) * 2018-03-28 2020-12-14 아센디스 파마 온콜로지 디비전 에이/에스 IL-2 conjugate
AU2019246390A1 (en) 2018-03-28 2020-08-06 Ascendis Pharma A/S Conjugates
KR20210113272A (en) 2019-01-04 2021-09-15 아센디스 파마 온콜로지 디비전 에이/에스 Sustained topical drug levels for innate immune agents
SG11202105833WA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Minimization of systemic inflammation
MX2021007706A (en) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists.
CA3125488A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
SG11202108735QA (en) * 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S Il-2 sequences and uses thereof
JP2024514095A (en) 2021-04-01 2024-03-28 アセンディス ファーマ エー／エス Use of long-acting growth hormone to treat diseases induced by inflammation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL78930A0 (en) 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
JPH0531189A (en) 1991-01-16 1993-02-09 Takeda Chem Ind Ltd 2-chamber type injector
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
ES2198414T3 (en) 1992-10-23 2004-02-01 Immunex Corporation PROCEDURES TO PREPARE SOLUBLE OLIGOMERIC PROTEINS.
SE9303918L (en) 1993-11-26 1995-05-22 Hans Lundstroem Device at a box
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100236771B1 (en) 1997-04-01 2000-02-01 성재갑 Hyaluronate microparticles for sustained release of drug
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
EP1037649B1 (en) 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001259111B2 (en) 2000-04-19 2005-12-08 Durect Corporation Sustained release formulations comprising growth hormone
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2467731A1 (en) 2001-11-20 2003-05-30 Pharmacia Corporation Chemically-modified human growth hormone conjugates
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (en) 2002-11-14 2006-03-02 シンタルガ・ビーブイ Prodrugs constructed as multiple self-detaching release spacers
DE60307881T2 (en) 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag POSITIONAL ISOMERS OF PEGYLATED INTERFERON ALPHA 2A
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
SI2932981T1 (en) 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
WO2005035553A2 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
EP1732607B1 (en) 2004-03-23 2019-05-15 Ascendis Pharma GmbH Polymeric prodrug with a self-immolative linker
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
KR101224781B1 (en) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 Formulations of human growth hormone comprising a non-naturally encoded amino acid
KR20070100299A (en) 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
SG160437A1 (en) 2004-12-22 2010-04-29 Ambrx Inc Modified human growth hormone
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
WO2006102659A2 (en) 2005-03-23 2006-09-28 Nektar Therapeutics Al, Corporation CONJUGATES OF AN hGH MOIETY AND A POLYMER
TW200716179A (en) 2005-06-15 2007-05-01 Novo Nordisk As Transglutaminase mediated conjugation of growth hormone
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
BRPI0615351A2 (en) 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag liquid formulations of pegylated growth hormone
EP2364735A3 (en) 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
US20070190163A1 (en) 2006-01-24 2007-08-16 Malaknov Michael P Technology for preparation of macromolecular microspheres
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
AU2008258548B2 (en) 2007-06-08 2014-07-10 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
EP2369005B1 (en) 2007-06-21 2013-04-03 Technische Universität München Biological active proteins having increased in vivo and/or in vitro stability
LT2237799T (en) 2008-02-01 2019-07-25 Ascendis Pharma A/S Prodrug comprising a self-cleavable linker
EP3050576B1 (en) * 2008-04-29 2021-03-31 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
PT2119726E (en) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii peptides derived from survivin and neurocan
RU2011140219A (en) 2009-03-05 2013-04-10 Асцендис Фарма Ас MEDIA INTERFERON ALPHA ON THE MEDIA
MX343925B (en) 2009-07-31 2016-11-29 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels.
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US9511122B2 (en) 2009-12-15 2016-12-06 Ascendis Pharma Growth Disorders Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
ES2691642T3 (en) 2010-05-21 2018-11-28 Xl-Protein Gmbh Biosynthetic proline / alanine random winding polypeptides and their uses
EP2908845A1 (en) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Fatty acid acylated amino acids for growth hormone delivery
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016109823A1 (en) 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Also Published As

Publication number Publication date
BR112017009798A2 (en) 2017-12-19
FR22C1029I2 (en) 2023-04-14
EP3653227A1 (en) 2020-05-20
EP3653227B3 (en) 2022-03-09
JP7431355B2 (en) 2024-02-14
DK3237014T5 (en) 2024-10-14
AU2020270494B2 (en) 2024-02-01
EP3653227B9 (en) 2023-03-08
FI3237014T3 (en) 2023-06-09
RU2718664C2 (en) 2020-04-13
PT3653227T (en) 2021-02-26
JP2024054177A (en) 2024-04-16
US10799563B2 (en) 2020-10-13
IL307773A (en) 2023-12-01
SG10202105511RA (en) 2021-07-29
EP3237014B1 (en) 2023-03-29
AU2020270494A1 (en) 2020-12-17
AU2015348633B2 (en) 2020-10-22
IL251906B2 (en) 2024-04-01
US20200390864A1 (en) 2020-12-17
WO2016079114A1 (en) 2016-05-26
EP4218823A3 (en) 2023-11-15
ES2864415T7 (en) 2022-05-12
RU2017121203A (en) 2018-12-19
KR20230152187A (en) 2023-11-02
AU2015348633C1 (en) 2021-02-11
CA2968282A1 (en) 2016-05-26
CY1123963T1 (en) 2022-05-27
CY2022013I1 (en) 2023-01-05
RS61734B2 (en) 2022-04-29
EP3237014A1 (en) 2017-11-01
KR20170084267A (en) 2017-07-19
NL301172I2 (en) 2022-06-16
FIC20220017I1 (en) 2022-06-03
DK3653227T3 (en) 2021-02-15
NO2022014I1 (en) 2022-05-12
NZ731779A (en) 2021-11-26
JP6783782B2 (en) 2020-11-11
IL251906B1 (en) 2023-12-01
SG11201703870UA (en) 2017-06-29
CY2022013I2 (en) 2023-01-05
KR102608645B1 (en) 2023-12-01
AU2024201227A1 (en) 2024-03-28
BR112017009798A8 (en) 2020-11-03
EP4218823A2 (en) 2023-08-02
DK3237014T3 (en) 2023-05-30
LTPA2022506I1 (en) 2022-06-10
MX2022009155A (en) 2022-08-16
US12133883B2 (en) 2024-11-05
PL3653227T3 (en) 2021-07-05
LT3653227T (en) 2021-03-25
HRP20210400T1 (en) 2021-04-16
ES2864415T3 (en) 2021-10-13
DK3653227T5 (en) 2023-08-21
NL301172I1 (en) 2022-04-29
PL3653227T6 (en) 2022-04-19
ES2864415T9 (en) 2023-05-23
RU2017121203A3 (en) 2019-05-30
AU2015348633A1 (en) 2017-05-18
JP2021020932A (en) 2021-02-18
RS61734B1 (en) 2021-05-31
EP3653227B1 (en) 2021-01-20
JP2022033787A (en) 2022-03-02
MX2017006113A (en) 2017-10-16
JP2023052300A (en) 2023-04-11
HRP20210400T4 (en) 2022-04-29
JP7210683B2 (en) 2023-01-23
US20170354716A1 (en) 2017-12-14
SI3653227T1 (en) 2021-04-30
HUS2200019I1 (en) 2022-06-28
JP2017535609A (en) 2017-11-30
ES2947818T3 (en) 2023-08-21
IL251906A0 (en) 2017-06-29
HUE053855T2 (en) 2021-07-28
JP6982156B2 (en) 2021-12-17
DK3653227T6 (en) 2022-04-11

Similar Documents

Publication Publication Date Title
FR22C1029I2 (en) NEW POLYMERIC HGH PRODRUGS
DK3134402T3 (en) 4-amino-imidazoquinoline
DK3183051T3 (en) LIQUID-TO-LUFTMEMBRANENERGIVEKSLERE
DK3006072T3 (en) Karadgang
DK3119396T3 (en) MUSCARINRECEPTORAGONISTER
MA55696A (en) COMBINATIONS
DK3102254T3 (en) injecting
DE112015001664A5 (en) Betätigungsaktuator
DK3183340T3 (en) TERMOLABILE EXONUCLEASER
DK3294287T3 (en) Prodrugs oxabicycloheptane
DK3154703T3 (en) FULLKAPPE-SNEKKECENTRIFUGE
DK3110439T3 (en) PCSK9-VACCINES
DK3288391T3 (en) Feed additive
DE112015005041A5 (en) GARGERÄTEVORRICHTUNG
DE102014000623A8 (en) Halbhohlnietelement
DK3009858T3 (en) SKYRADAR
DE112015001633A5 (en) Betätigungsaktuator
DK3091875T3 (en) VIPBAR TABURET
DE202014005655U8 (en) llluminationsvorrichtung
TH177000B (en) Polymer degradation
ES1147358Y (en) IMPROVED SERVILLETERO
ITUB20153420A1 (en) PATCH
DE112015005055A5 (en) Gargerätevorrichtung
DE112015004618A5 (en) set
ES1134780Y (en) SKATEBOARD